I7
I76.F Ironwood Pharmaceuticals Inc
- Market cap
- EUR 709M
- P/E
- 5.6x
- P/B
- 2.60x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is I76.F undervalued?
Graham numberI76.F trades 19.9% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ironwood Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Ironwood Pharmaceuticals Inc yet.
Ironwood Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZE…
Full company profileIronwood Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ironwood Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 274M | 298M | 347M | 428M | 390M | 414M | 411M | 443M | 351M | 296M | 470M |
| Gross Profit | 272M | 279M | 314M | 405M | 386M | 414M | 411M | - | - | - | - |
| Operating Income | -41.7M | -108M | -102M | 117M | 158M | 232M | 250M | 168M | 95.7M | 119M | 327M |
| EBITDA | - | -66.0M | -230M | 101M | 142M | 232M | 260M | -925M | 100M | 105M | 334M |
| Net Income | -81.7M | -117M | -282M | 21.5M | 106M | 528M | 175M | -1.00B | 880K | 24.0M | 203M |
| EPS | - | -0.78 | -1.83 | 0.14 | 0.66 | 3.26 | 1.14 | -6.41 | 0.01 | 0.15 | 1.22 |
| Balance Sheet | |||||||||||
| Total Assets | 710M | 606M | 332M | 403M | 559M | 1.13B | 1.10B | 471M | 351M | 397M | 291M |
| Total Liabilities | 643M | 596M | 528M | 496M | 497M | 521M | 448M | 817M | 652M | 659M | 388M |
| Shareholders' Equity | 66.7M | 9.85M | -196M | -93.3M | 62.6M | 606M | 652M | -346M | -301M | -262M | -97.2M |
| Cash & Short-term Investments | 54.0M | 126M | 173M | 177M | 363M | 620M | 656M | 92.2M | 88.6M | 215M | 86.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -25.9M | -101M | -70.9M | 10.7M | 169M | 262M | 274M | 227M | 104M | 127M | 174M |
| Capital Expenditure | 104M | 2.80M | 351K | 7.19M | 1.84M | 265K | 136K | 35.0K | 142K | 34.0K | 0.00 |
| Free Cash Flow | - | -104M | -79.5M | 3.54M | 167M | 262M | 274M | 227M | 103M | 127M | 174M |
| Ratios | |||||||||||
| ROE | -122.5% | -1,187.4% | - | - | 169.5% | 87.2% | 26.8% | - | - | - | - |
| ROA | -11.5% | -19.3% | -85.0% | 5.3% | 19.0% | 46.9% | 15.9% | -212.8% | 0.3% | 6.1% | 69.7% |
| Net Profit Margin | -29.8% | -39.2% | -81.5% | 5.0% | 27.3% | 127.7% | 42.6% | -226.4% | 0.3% | 8.1% | 43.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Ironwood Pharmaceuticals Inc dividends
Ironwood Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns Ironwood Pharmaceuticals Inc
- Insiders 3.23%
- Institutions 96.77%
- Public & others 0.00%
- Shares outstanding 166M
- Free float 137M
Ironwood Pharmaceuticals Inc company profile
- Company name
- Ironwood Pharmaceuticals Inc
- Ticker
- I76.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 100
- Fiscal year end
- December
- Address
- 100 Summer Street, Boston, MA, United States, 02110
- Phone
- 617 621 7722
- Website
- ironwoodpharma.com
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Ironwood Pharmaceuticals Inc management
8- Mr. Thomas A. McCourtCEO & Director · born 1957
- Ms. Tammi GaskinsSenior Vice President & Chief Commercial Officer · born 1973
- Mr. Ronald SilverSenior VP, Interim CFO, Corporate Controller & Chief Accounting Officer · born 1982
- Dr. Rosario Lobrutto M.B.A., M.S., Ph.D.VP & Global Head of Technical Operations
- Mr. Chris StammVice President of Investor Relations & Communications
- Mr. John MinardoSenior VP, Chief Legal Officer & Secretary · born 1976
- Mr. Jeff RubertiChief Strategy Officer
- Dr. Jeffrey Silber M.D.Chief Medical Officer, Head of Research & Drug Development